Kiniksa Pharmaceuticals Raises FY2026 Sales Guidance from $900.000M-$920.000M to $930.000M-$945.000M vs $913.245M Est

Benzinga Newsdesk www.benzinga.com Positive 94.4%

Neg 0% Neu 0% Pos 94.4%

Kiniksa Pharmaceuticals (NASDAQ:KNSA) raises FY2026 sales outlook from $900.000 million-$920.000 million to $930.000 million-$945.000 million vs $913.245 million estimate.